High materiality7/10
Teva initiated with an Outperform at Oppenheimer
Why it may matterVerify against the original reporting
Outperform
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer initiated Teva with Outperform; target $50; posted price $39.52.
- Outperform initiation; target $50 vs price $39.52.
Key facts
- 01
Target: $50
- 02
Posted price: $39.52
- 03
Analyst firm: Oppenheimer
- 04
Analyst: Les Sulewski
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.